Suggestions(5)
Exact(1)
Below, we describe the procedure and pipeline for obtaining low-degeneracy primers targeted to a selected gene (with emphasis given the taxonomic level that will be assayed by the specific primer pair), and then outline the method, originally reported by Faith et al. (2013), for producing sets of phased, barcoded primers through an annealing/amplification step.
Similar(59)
This paper describes the validation of three of the assays that will be employed during the phase I trial of AEG 35156/GEM 640.
Such protein-based markers would be well-adapted to high throughput screening assays that will be used to determine the protection status of individuals post vaccination.
In addition, we tested for human metapneumovirus (HMPV), human parainfluenza viruses (HPIV) serotypes 1, 2, and 3, adenovirus, and influenza viruses type A and B using RT-PCR assays that will be described elsewhere [14].
Method validation data are presented on three pharmacodynamic assays that will be utilised during this trial.
In this respect, choosing the appropriate assay that will be accurate, reliable and convenient enough will be of great importance for application in the clinical setting.
The biology of the underlying mechanisms is becoming characterized and will thus allow development of mechanistically based in vitro assays that will be scientifically validated and thus acceptable to regulatory agencies.
This includes identification of the sequence surrounding a SNP that will be useful in designing the assay (for example, the oligos or primers for an array, ligation, or single base extension reactions), or primer prediction and restriction enzyme selection.
But when this is necessary, it will be crucial to plan, even for early phase studies, to obtain enough samples so that some can be stored and then reanalyzed using the version of the assay that will be submitted for health authority approval.
We plan future simplification of the test to a dipstick dye assay format that will be rapid, cheap and not requiring any equipment.
This is a daunting challenge that few, if any, labs are currently embracing, but it may be that particular steps can be addressed in isolation as structural biologists have recently had considerable success expressing recombinant membrane transport components that will be invaluable for such in vitro assays.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com